Loading...
Loading...
Perrigo Company (Nasdaq: PRGO;
TASE) today announced that it has agreed to settle its Hatch-Waxman litigation
relating to Acetadote® (acetylcysteine) injection brought by Cumberland
Pharmaceuticals, Inc. ("Cumberland"). Under the terms of the settlement,
Perrigo can launch a generic version of Acetadote® (acetylcysteine) injection
upon expiration of the patents in May 2026. In addition, Perrigo entered into
an agreement with Cumberland wherein Perrigo can distribute Cumberland sourced
authorized generic product upon generic market formation.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in